HRID18561

反应详情

EQUATION

反应方程式

REACTANTS

反应物

结构：CC(C)N1CCC(NC(=O)c2nc3cc(C(=O)O)ccc3n2CC(=O)Nc2ccc(Cl)cn2)CC1

HCID11317994

未命名化合物

HCID23090214

1,4-Oxazepane--hydrogen chloride (1/1)

C5H12ClNO

PRODUCTS

生成物

结构：CC(C)N1CCC(NC(=O)c2nc3cc(C(=O)N4CCCOCC4)ccc3n2CC(=O)Nc2ccc(Cl)cn2)CC1

HCID67012632

未命名化合物

PROCEDURE

实验过程

1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-([1,4]oxazepane-4-carbonyl)-1H-benzoimidazole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide was prepared by a procedure according to example 22 starting from 147.8 mg (0.296 mmol) 1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-2-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-benzoimidazole-5-carboxylic acid and 44.8 mg (0.326 mmol) homomorpholine-hydrochloride. The title compound was obtained as its formiate. Subsequent transformation to the corresponding acetate gave a white amorphous solid.

WORKUP

后处理

custom1-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-5-([1,4]oxazepane-4-carbonyl)-1H-benzoimidazole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide was prepared by a procedure

来源与证据

来源类型: Open Reaction Database
ORD 记录: ord-2344cad02f82431fa5991cdeacc6d8ac
来源数据集: uspto-grants-2010_06
DOI: 10.6084/m9.figshare.5104873.v1
专利: US07741341B2
来源说明: uspto-grants-2010_06

反应 SMILES

[Cl:1][C:2]1[CH:3]=[CH:4][C:5]([NH:8][C:9]([CH2:11][N:12]2[C:16]3[CH:17]=[CH:18][C:19]([C:21]([OH:23])=O)=[CH:20][C:15]=3[N:14]=[C:13]2[C:24](=[O:35])[NH:25][CH:26]2[CH2:31][CH2:30][N:29]([CH:32]([CH3:34])[CH3:33])[CH2:28][CH2:27]2)=[O:10])=[N:6][CH:7]=1.[CH2:36]1[CH2:42][O:41][CH2:40][CH2:39][NH:38][CH2:37]1.Cl>>[CH:32]([N:29]1[CH2:28][CH2:27][CH:26]([NH:25][C:24]([C:13]2[N:12]([CH2:11][C:9](=[O:10])[NH:8][C:5]3[CH:4]=[CH:3][C:2]([Cl:1])=[CH:7][N:6]=3)[C:16]3[CH:17]=[CH:18][C:19]([C:21]([N:38]4[CH2:37][CH2:36][CH2:42][O:41][CH2:40][CH2:39]4)=[O:23])=[CH:20][C:15]=3[N:14]=2)=[O:35])[CH2:31][CH2:30]1)([CH3:34])[CH3:33]